TABLE 1.
In vitro activities of ceftazidime-avibactam and comparator agents tested against 7,062 P. aeruginosa isolates collected in 2012 to 2014 from patients in four geographic regions
| Region (no. of isolates) | Antimicrobial agenta | MIC90 (μg/ml) | % Susceptibleb |
|---|---|---|---|
| All (7,062) | Ceftazidime-avibactam | 8 | 92.0 |
| Ceftazidime | 64 | 77.0 | |
| Cefepime | >16 | 78.3 | |
| Piperacillin-tazobactam | >128 | 68.6 | |
| Doripenem | >4 | 74.3 | |
| Meropenem | >8 | 72.7 | |
| Imipenem | >8 | 61.4 | |
| Colistin | 1 | 99.5 | |
| Amikacin | 32 | 89.4 | |
| Levofloxacin | >4 | 71.9 | |
| Europe (3,893) | Ceftazidime-avibactam | 8 | 92.6 |
| Ceftazidime | 64 | 77.4 | |
| Cefepime | 16 | 78.8 | |
| Piperacillin-tazobactam | >128 | 69.4 | |
| Doripenem | >4 | 74.4 | |
| Meropenem | >8 | 72.9 | |
| Imipenem | >8 | 60.3 | |
| Colistin | 1 | 99.5 | |
| Amikacin | 32 | 89.7 | |
| Levofloxacin | >4 | 71.3 | |
| Asia/South Pacific (1,392) | Ceftazidime-avibactam | 8 | 93.2 |
| Ceftazidime | 64 | 78.1 | |
| Cefepime | 16 | 80.2 | |
| Piperacillin-tazobactam | >128 | 71.3 | |
| Doripenem | >4 | 78.5 | |
| Meropenem | >8 | 77.4 | |
| Imipenem | >8 | 67.0 | |
| Colistin | 1 | 99.5 | |
| Amikacin | 8 | 94.4 | |
| Levofloxacin | >4 | 77.2 | |
| Latin America (1,088) | Ceftazidime-avibactam | 16 | 88.7 |
| Ceftazidime | 64 | 71.5 | |
| Cefepime | >16 | 73.2 | |
| Piperacillin-tazobactam | >128 | 62.3 | |
| Doripenem | >4 | 66.8 | |
| Meropenem | >8 | 64.9 | |
| Imipenem | >8 | 57.2 | |
| Colistin | 1 | 99.4 | |
| Amikacin | >32 | 81.8 | |
| Levofloxacin | >4 | 64.7 | |
| Middle East/Africa (689) | Ceftazidime-avibactam | 8 | 91.7 |
| Ceftazidime | 32 | 80.8 | |
| Cefepime | 16 | 79.5 | |
| Piperacillin-tazobactam | >128 | 68.8 | |
| Doripenem | >4 | 77.1 | |
| Meropenem | >8 | 74.8 | |
| Imipenem | >8 | 63.3 | |
| Colistin | 1 | 99.6 | |
| Amikacin | 16 | 90.1 | |
| Levofloxacin | >4 | 75.9 |
a
Colistin was tested in the presence of a final concentration of 0.002% polysorbate 80.
b
Values are based on CLSI breakpoints, except for ceftazidime-avibactam, for which FDA breakpoints were used.